The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry
Abstract
Background The contribution of diabetes to the burden of heart failure (HF) remains largely undescribed. Assessing diabetes temporal trends among US patients hospitalized with HF and their relation with quality measures in real-world practice can help to define this burden.Methods Using data from the Get With the Guidelines-Heart Failure registry, we assessed temporal trends in diabetes prevalence among patients with HF and in subgroups with reduced ejection fraction (HFrEF; EF < 40%), borderline EF (HFbEF; 40%≤EF <50%), or preserved EF (HFpEF; EF ≥ 50%), hospitalized between 2005 and 2015. Logistic regression was used to assess whether in-hospital outcomes and HF quality of care were related to trends.Results Among 364,480 HF hospitalizations, 160,171 had diabetes (44.0% overall, 41.8% in HFrEF, 46.7% in HFbEF, 45.5% in HFpEF). There was a temporal increase in diabetes frequency in HF patients (43.2%-45.8%; P trend <.0001), including among those with HFrEF (42.0%-43.6%; P trend <.0001), HFbEF (46.0%-49.2%; P trend <.0001), or HFpEF (43.6%-46.8%, P trend <.0001). Diabetic patients had a longer hospital stay (adjusted odds ratio 1.14, 95% CI 1.12-1.16), but lower in-hospital mortality (adjusted odds ratio 0.93 [0.89-0.97]) compared with those without diabetes, with limited differences in quality measures. Temporal trends in diabetes were not associated with in-hospital mortality or length of stay. There were no temporal interactions of most HF quality measures with diabetes status.Conclusions Approximately 44% of hospitalized HF patients have diabetes, and this proportion has been increasing over the past 10years, particularly among those patients with new-onset HFpEF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 45% of people admitted for HFpEF have diabetes, and most people with HFpEF have obesity (320,321).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [320]
In the citing paper
“Approximately 45% of people admitted for HFpEF have diabetes, and most people with HFpEF have obesity (320,321).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [320]
In the citing paper
“Increasing evidence has demonstrated the benefits of GLP-1 RA or dual GIP/GLP-1 RA on symptoms and outcomes for people with HFpEF and obesity, and while most people with HFpEF have obesity, approximately 45% have diabetes (304,305).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [304]
In the citing paper
“Increasing evidence has demonstrated the benefits of GLP-1 RA or dual GIP/GLP-1 RA on symptoms and outcomes for people with HFpEF and obesity, and while most people with HFpEF have obesity, approximately 45% have diabetes (304,305).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [304]
In the citing paper
“Increasing evidence has demonstrated the benefits of GLP-1 RA or dual GIP/GLP-1 RA on symptoms and outcomes for people with HFpEF and obesity, and while most people with HFpEF have obesity, approximately 45% have diabetes (304,305).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [304]
In the citing paper
“In the past decade, HFpEF has taken on great importance in individuals with diabetes who represent about 45% of people suffering from this type of HF, with a significantly increasing proportion in those with new-onset HFpEF [73].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [73]
In the citing paper
“and a slight increase in the prevalence was reported in North America over time.49,52”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [49]
In the citing paper
“In registries of hospitalized HF patients in North America and Europe, the prevalence of T2DM is around 40-45%, 49 -52”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [49]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citationEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION
Tarver, T. (2014) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,595
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationInternational Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Forecasting the Impact of Heart Failure in the United States
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,872
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–160 of 160
Ertugliflozin + metformin as a treatment option for type 2 diabetes
Athyros, V. G., Boutari, C., & Karagiannis, A. I. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1939676 · Cited by 5
The Concept of "Heart Failure with Preserved Ejection Fraction": Time for a Critical Reappraisal
Fragasso, G. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2407202 · Cited by 5
Abushamat, L. A., Enge, D., Fujiwara, T., Schäfer, M., Clark, E. W., Englund, E. K., Scalzo, R. L., Johnston, A., Rafferty, D., Schauer, I. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003534 · Cited by 6
Dobrowolska, M., Miękus, P., Świątczak, M., Raczak, G., & Daniłowicz‐Szymanowicz, L. (2021) · Kardiologia Polska · doi:10.33963/kp.15763 · Cited by 5
Koziolova, N. A., Karavaev, P. G., & Veklich, A. S. (2020) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2020-1-2-93-101 · Cited by 4
Trimarco, B., Barbato, E., Izzo, R., & Morisco, C. (2022) · Diabetes Care · doi:10.2337/dci22-0032 · Cited by 4
Psychosocial Syndemics and Multimorbidity in Patients with Heart Failure
Freedland, K. E., Skala, J. A., Carney, R. M., Steinmeyer, B. C., & Rich, M. W. (2021) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20210006 · Cited by 4
Health Care Expenditure in United States Adults With Heart Failure With and Without Diabetes
Shah, C. H., Fonarow, G. C., & Echouffo-Tcheugui, J. B. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.07.027 · Cited by 4
Arévalo‐Lorido, J. C., Carretero‐Gómez, J., Huelgas, R. G., López, R. Q., Ramos, M. F. D., Serrado-Iglesias, A., Ruiz-Laiglesia, F., Franco, Á. G., Rodrigo, J. M. C., & Montero-Pérez-Barquero, M. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.10.008 · Cited by 4
Semaglutide—a new treatment for obesity-related heart failure with preserved ejection fraction?
Donal, E., L'Official, G., & Istrătoaie, S. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00653-6 · Cited by 3
Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy
Shafaati, T., & Gopal, K. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13193 · Cited by 3
Sun, J., Xie, Z., Ye, M., He, X., Dong, Y., Liu, C., & Zhu, W. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14689 · Cited by 2
Treatment of Diabetes in Patients with Heart Failure
Bowes, C. D., Lien, L. F., & Butler, J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1032-5 · Cited by 3
Arévalo‐Lorido, J. C., Carretero‐Gómez, J., Huelgas, R. G., López, R. Q., Ramos, M. F. D., Serrado-Iglesias, A., Ruiz-Laiglesia, F., Franco, Á. G., Rodrigo, J. C., Montero-Pérez-Barquero, M., et al. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2019.10.001 · Cited by 3
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_6 · Cited by 3
Shlyakhto, E. V., Belenkov, Y. N., Boytsov, S. A., Вадимовна, В. С., Galyavich, A. S., Глезер, М. Г., Звартау, Н. Э., Kobalava, Z. D., Lopatin, Y. M., VIu, M., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6519 · Cited by 3
Yang, Y., Zhou, Y., Cao, Y., Dong, Y., Liu, C., & Zhu, W. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.04.020 · Cited by 2
Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus
Adamu, U. G., Mpanya, D., Patel, A. K., & Tsabedze, N. (2022) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2022.2113206 · Cited by 2
Tie, E. N., Nanayakkara, S., Vizi, D., Mariani, J. A., & Kaye, D. M. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.12.008 · Cited by 3
Arévalo‐Lorido, J. C., Carretero‐Gómez, J., Rubini, A., Félix-Redondo, F. J., Pérez-Monteoliva, N. R. R., González, M. H., Jarén, E. V., Castellano, B. C., González-Fernández, R., & Fernandez-Berges, D. J. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2365769 · Cited by 2
Shafrin, J. T., Wang, S., Kim, J., Sikirica, S., & Sandhu, A. T. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.23236 · Cited by 2
A LEADER in the management of type 2 diabetes and cardiorenal disease
Verma, S., Leiter, L. A., Latter, D. A., & Bhatt, D. L. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.03.134 · Cited by 2
Vícha, M., Skála, T., Jelínek, L., Pavlů, L., Jarkovský, J., Dušek, L., Benešová, K., & Táborský, M. (2021) · Biomedical Papers · doi:10.5507/bp.2021.069 · Cited by 2
The world congress on insulin resistance, diabetes, and cardiovascular disease ( WCIRDC )
Bloomgarden, Z. T. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13260 · Cited by 2
SGLT2 inhibitors in acute decompensated heart failure, what do we know?
Евгеньевна, Л. А., Николаевна, Н. С., Жиров, И. В., & Tereshchenko, S. N. (2022) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.04.201449 · Cited by 2
The Prognostic Efficacy of DPP-4 Inhibitors in Asian HFpEF
Chikata, Y., Iwata, H., & Minamino, T. (2023) · JACC Asia · doi:10.1016/j.jacasi.2022.11.008 · Cited by 2
Diabetes, Functional Status, and Mortality in Chronic Heart Failure
Noumegni, S. R., Kazé, A. D., Bertoni, A. G., Fonarow, G. C., & Echouffo-Tcheugui, J. B. (2024) · Diabetes Care · doi:10.2337/dc24-1586 · Cited by 1
Santos‐de‐Araújo, A. D., Dibai, D. B., Dourado, I. M., Goulart, C. D. L., Marinho, R. S., Mantovani, J., de Souza, G. S., dos Santos, P. B., Roscani, M. G., Phillips, S. A., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01464-z · Cited by 1
Shafrin, J. T., Wang, S., Kim, J., & Sikirica, S. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.4.386 · Cited by 1
Hong, Y., Nasim, U., Dorken‐Gallastegi, A., Iyanna, N., Woolley, B. E., Machinski, S. N., Hickey, G., Keebler, M., Horn, E. T., & Kaczorowski, D. J. (2025) · Clinical Transplantation · doi:10.1111/ctr.70355 · Cited by 1
The Impact of Risk Factors and Comorbidities on Heart Failure in the Aging Population
Flores, R. C., Talukder, F. S., & Rabinovich-Nikitin, I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125296 · Cited by 1
Timar, B., Braha, A., Grigorică, L., Gaiţă, L., & Timar, R. Z. (2020) · Timişoara Medical Journal · doi:10.35995/tmj20200101 · Cited by 1
Liu, Y., Yu, J., Hu, H., Pu, S., Wu, H., Ma, Y., Yang, W., Fang, C., Sun, F., & Wang, H. (2025) · Aging · doi:10.18632/aging.206261 · Cited by 1
Lo scompenso cardiaco a 360 gradi
Gnerre, G. E. P., & Pasquale, G. D. (2021) · Italian Journal of Medicine · doi:10.4081/itjm.q.2021.2 · Cited by 1
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1423962 · Cited by 1
The Arrhythmogenic Impact of Heart Failure With Preserved Ejection Fraction on Diabetics
Mubasher, M., Mohamed, M. F. H., Danjuma, M. I.-M., Magdi, M., Hanafi, A., Syed, T. A., Alweis, R. L., Alqawasma, M., Rao, M. C., & Hoefen, R. J. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.11.022
A possible follow‐up method for diabetic heart failure patients
Koç, Ş. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14794
Features of course and treatment of chronic heart failure in patients with diabetes mellitus type 2
Gorb, Y. G., Strona, V. I., Tkachenko, O. V., & Ryabukha, V. V. (2020) · Medicine Today and Tomorrow · doi:10.35339/msz.2020.86.01.03
A Paixón e a Semana Santa en Galicia: coñecemento do medio cultural galego
Gómez, F. S. L. (2002) · Dialnet (Universidad de la Rioja)
Rudyk, I. S., Babichev, D., Medentseva, O., & Gasanov, I. (2022) · ScienceRise Medical Science · doi:10.15587/2519-4798.2022.258497
Advances in Research on Heart Failure with Preserved Ejection Fraction
赵, 小. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.1281099
Lu, Z. Q., McCourt, E. M., Goodhew, K., Gupta, D., Chuan, F., Mok, L., Peters, R., Ha, T., Fowler, D. H., Dobbyn, D., et al. (2022) · Internal Medicine Journal · doi:10.1111/imj.15993
Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual
Peter, P. R., & Inzucchi, S. E. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_37
Heart Failure and Cardiac Dysfunction in Diabetes
Afari, M. E., & Givertz, M. M. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_27
Sadiq, M. A., Salih, A. A., & Jamil, N. F. (2023) · International Journal of Membrane Science and Technology · doi:10.15379/ijmst.v10i2.3153
Diabetes, prediabetes, and heart failure
Rosano, G. M. C., Butler, J., Seferovic, P. M., Seferović, J. P., & Cosentino, F. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780198891628.003.0073
Ai, S., Wang, X., Wang, S., Zhao, Y., Guo, S., Li, G., Chen, Z., Lin, F., Guo, S. J., Li, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20098493
Effect of SGLT-2 Inhibitors on Zebrafish Model with Diabetic Heart Failure
-, S. Y. W., Wankhade, A. M., Vyas, J. V., & Paithankar, V. (2024) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2024.v06i03.22693
Dey, S., Bhattacharyya, S., & Sinharay, M. (2024) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v15i8.65217
SGLT2 Inhibitors and Mechanism of Cardiovascular Benefits in Type 2 Diabetes
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_2
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Ai, S., Wang, X., Wang, S., Zhao, Y., Guo, S., Li, G., Chen, Z., Lin, F., Guo, S., Li, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20098490
Vuori, M. A., Reinikainen, J., Söderberg, S., Bergdahl, E., Jousilahti, P., Tunstall-Pedoe, H., Zeller, T., Westermann, D., Sans, S., Linneberg, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16696264
Rôle de la dysfonction endothéliale dans la physiopathologie de l'insuffisance cardiaque
Guimbal, S. (2020) · theses.fr (ABES) · doi:10.70675/293b97bezffdfz4208z86aez69830e83be3d
Hiura, K., Masuda, H., Sakunami, M., & Yamashita, M. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70335
Chen, Z., Cheng, J., Huang, C., Lin, T.-T., Ting-Chuan, W., Yang, Y.-Y., Chuang, S.-L., Tsai, C., Lin, L., Hung, C., et al. (2026) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztag083
Mineralocorticoid receptor overactivation in heart failure with preserved ejection fraction
Kobayashi, M., Pitt, B., & Zannad, F. M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag578
Zhang, Q., Wan, J., Li, B., Sun, Z., Li, W., & Zang, H. (2026) · Research Square · doi:10.21203/rs.3.rs-10718477/v1
Immunometabolic regulation of cardiac macrophages in heart failure with preserved ejection fraction
Liang, J., Su, M., Liu, R., Li, T., Qin, Z., & Wáng, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1896936
Diabetic Heart Failure: Epidemiology and Prognosis
Bamba-Kamagaté, D., Yves-Cédric, K. M., Stéphane, K. K. G., Florent, K., Matokoma, D. M., Ehouman, E., & Jean-Baptiste, A.-K. (2026) · Journal of Cardiac Critical Care TSS · doi:10.25259/jccc_67_2025
Metadata
- Authors
- Echouffo-Tcheugui, J. B., Xu, H., DeVore, A. D., Schulte, P. J., Butler, J., Yancy, C. W., Bhatt, D. L., Hernandez, A. F., Heidenreich, P. A., & Fonarow, G. C.
- Affiliations
- Brigham and Women's Hospital (US)
- Duke Clinical Research Institute (US)
- Mayo Clinic (US)
- Stony Brook University (US)
- Northwestern University (US)
- VA Palo Alto Health Care System (US)
- University of California, Los Angeles (US)
- Corresponding author
- Echouffo-Tcheugui, Justin B.
- ORCID
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 182
- Pages
- 9-20
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W2508250664
- Cited by
- 160
- References
- 41
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 24 · 2023: 16 · 2022: 28 · 2021: 21 · 2020: 22 · 2019: 13 · 2018: 11 · 2017: 5
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of California, Los Angeles
- Ahmanson Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes mellitus, heart failure, temporal trends, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, in-hospital mortality, length of hospital stay, quality of care, new-onset diabetes, hospitalized patients
- MeSH terms
- Aged, Aged, 80 and over, Diabetes Mellitus, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Registries, Socioeconomic Factors, Stroke Volume, United States, Comorbidity, Prevalence, Hospital Mortality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review